Ozekibart's 52% Reduction in Risk Sparks 70% Jump Amid Concerns Over Liver Safety
- Inhibrx Biosciences’ ozekibart showed 52% reduced disease progression risk in chondrosarcoma, driving a 70% post-market stock surge. - Combination trials in colorectal and Ewing sarcoma showed 23%–64% response rates, suggesting broader oncology potential. - Hepatotoxicity concerns led to monitoring strategies, reducing adverse events to 11.8% in ozekibart group. - Company plans 2026 BLA submission; stock surged 63% pre-market after prior 10% decline.
Shares of Inhibrx Biosciences (NASDAQ:INBX) soared by more than 70% in after-hours trading on October 23, 2025, after the company announced encouraging Phase 2 trial data for its investigational cancer therapy ozekibart (INBRX-109) in chondrosarcoma, a rare and aggressive bone malignancy that currently lacks approved systemic treatments, as reported by an
Ozekibart’s safety profile was generally acceptable, though liver toxicity was identified as a significant issue. Early in the study, a fatal liver-related incident led to the adoption of risk mitigation strategies, including excluding patients with advanced liver dysfunction and closely monitoring liver function during the initial treatment cycles. These interventions reduced the rate of treatment-related liver side effects to 11.8% in the ozekibart group versus 4.5% in the placebo group, with most cases being mild or moderate in severity, as detailed in
In addition to chondrosarcoma,
The company intends to file a Biologics License Application (BLA) with the U.S. Food and Drug Administration in the second quarter of 2026, according to Investing.com. Comprehensive data from the ChonDRAgon study will be presented at the Connective Tissue Oncology Society Annual Meeting on November 14, 2025, as noted by Tokenist.
The market responded strongly to the announcement, with
Financially, Inhibrx has a market capitalization near $457 million and maintains strong liquidity, with a current ratio close to 5, according to
INBX shares have climbed 140% year-to-date, reflecting strong investor confidence, though some warn that commercial success will depend on overcoming regulatory challenges and proving long-term effectiveness. With no approved therapies for chondrosarcoma, ozekibart’s potential to be first to market has drawn parallels to other breakthrough drugs in specialized oncology fields, according to Stocktwits.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
AI’s Risky Bet on Volatility Fails: 80% Plunge Reveals Market’s Heavy Dependence
- Alpha Arena's report reveals 80% capital loss in AI-driven trading models, exposing algorithmic strategy flaws amid market volatility. - BigBear.ai faces 18% revenue decline and $90M operating loss due to Trump-era spending cuts, despite defense tech partnerships. - C3.ai struggles with CEO departure, legal disputes, and 50% stock drop, contrasting UiPath's 14% AI-powered revenue growth and 108% retention rate. - Market skepticism grows as AI volatility risks emerge, with quantum computing still distant
Bitcoin News Update: Institutions Invest $314 Million in Bitcoin as Bull Market Targets $115,000
- Bitcoin approaches $115k as RUL drops below 5%, signaling strong long-term holder confidence. - Institutions like BlackRock deposit $314M BTC/ETH into Coinbase, while Fed explores crypto payment accounts. - ETF inflows favor Bitcoin over Ethereum, but derivatives hedging and macro risks pose breakout challenges. - Technical indicators show consolidation with elevated open interest, awaiting regulatory clarity for next moves.

Cardano News Today: Cardano's $0.62 at a Critical Point: Bulls Eye $2.96, Bears Aim for $0.50
- Cardano (ADA) faces a 20% monthly decline near $0.64, with analysts divided on its potential for a bullish breakout or further losses. - A critical $0.63–$0.64 support defense could trigger a 333% surge to $2.96, while a breakdown below $0.62 risks a drop to $0.50. - Whale accumulation of 200M ADA tokens and stable market cap ($22–$25B) contrast with broader crypto market weakness affecting ADA, Bitcoin, and Ethereum. - Short-term momentum indicators show improved buying pressure above $0.67–$0.68, but f

Healthcare organizations resolve privacy litigation to mitigate risks amid increased examination of tracking technologies
- Pomona Valley Hospital settles $600,000 lawsuit over unauthorized Facebook Pixel tracking on its website, alleged to violate California privacy laws. - The class-action, filed in 2023, claimed the hospital illegally intercepted user data via tracking tools during patient portal logins between 2019-2022. - Settlement terms include pro-rata payments to affected California residents, with funds covering legal fees and administrative costs, though the hospital denies wrongdoing. - The case reflects heightene
